Sat Mar 28 22:18:43 SGT 2015  
    Hepatitis B, Philippines
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment
28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing

Hepatitis B, Philippines


Hepatitis B, Philippines @hepatitisb_biz: Hepatitis B symptoms in men/women, screening/diagnosis, testing/check and treatment, Philippines - Private and confidential service.

Keywords: Hepatitis B Philippines, Philippines Hepatitis B, Hepatitis B.


Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Hepatitis B, Philippines
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Budget airlines based in Singapore:

Budget airlines operating in Singapore:

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute HIV rapid test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute HIV rapid test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

Location reference

Latest News

A rheumatology perspective on cutaneous vasculitis: assessment and investigation for the non‐rheumatologist
Fri, 27 Mar 2015 18:07:45 +0100 | International Wound Journal

Baruch S. Blumberg Institute Recruits World-Class Hepatitis B...
Fri, 27 Mar 2015 15:10:07 +0100 | PRWeb: Medical Pharmaceuticals
‘All-star’ researchers intend to develop breakthrough therapies for the viral liver infection within 3 years(PRWeb March 26, 2015)Read the full story at (Source: PRWeb: Medical Pharmaceuticals)

Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection
Fri, 27 Mar 2015 05:48:09 +0100 | Expert Opinion on Drug Safety
Expert Opinion on Drug Safety, Ahead of Print. (Source: Expert Opinion on Drug Safety)

GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease
Fri, 27 Mar 2015 00:00:00 +0100 | Journal of Cellular Physiology
The chaperone GRP78/Dna K is conserved throughout evolution down to prokaryotes. The GRP78 inhibitor OSU‐03012 (AR‐12) interacted with sildenafil (Viagra) or tadalafil (Cialis) to rapidly reduce GRP78 levels in eukaryotes and as a single agent reduce Dna K levels in prokaryotes. Similar data with the drug combination were obtained for: HSP70, HSP90, GRP94, GRP58, HSP27, HSP40 and HSP60. OSU‐03012/sildenafil treatment killed brain cancer stem cells and decreased the expression of: NPC1 and TIM1; LAMP1; and NTCP1, receptors for Ebola/Marburg/Hepatitis A, Lassa fever, and Hepatitis B viruses, respectively. Pre‐treatment with OSU‐03012/sildenafil reduced expression of the coxsakie and adenovirus receptor in parallel with it also reducing the ability of a serotype 5 adenovirus or coxs...

Cutaneous Manifestations of Viral Hepatitis
Thu, 26 Mar 2015 00:00:00 +0100 | Current Infectious Disease Reports

Using Ultrasonic Transient Elastometry (FibroScan) to Predict Esophageal Varices in Patients with Viral Liver Cirrhosis
Thu, 26 Mar 2015 00:00:00 +0100 | Ultrasound in Medicine and Biology
The correlation between liver stiffness (LS), measured by ultrasonic transient elastometry (FibroScan), and the presence and severity of esophageal varices (EV) in patients with viral cirrhosis of the liver has not been well documented to date. The study described here investigated the value of using FibroScan to predict EV. Patients with cirrhosis (200 patients: 167 cases caused by hepatitis B virus and 33 cases caused by hepatitis C virus) underwent both upper gastrointestinal endoscopy and FibroScan. (Source: Ultrasound in Medicine and Biology)

HBV exposure matures infants' immune systems
Wed, 25 Mar 2015 15:08:19 +0100 | ScienceDaily Headlines
Hepatitis B Virus Infection exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life, a new study concludes. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B. (Source: ScienceDaily Headlines)

Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B
Wed, 25 Mar 2015 00:00:00 +0100 | BMC Infectious Diseases

The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy
Wed, 25 Mar 2015 00:00:00 +0100 | BMC Infectious Diseases

Adaptation of the hepatitis B virus core protein to CD8+ T‐cell selection pressure
Wed, 25 Mar 2015 00:00:00 +0100 | Hepatology
Conclusion: Viral sequence analysis allows identification of HLA class I–restricted epitopes under reproducible selection pressure in HBV core; the possibility of viral escape from CD8 T‐cell immune pressure needs attention in the context of therapeutic vaccination against HBV. (Hepatology 2015) (Source: Hepatology)